MagVenture TMS: New CE approvals for addiction, OCD, and clinical benefit for comorbid anxiety

Please note that this presentation is intended for healthcare professionals but not intended for a US audience.
MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD). In addition, MagVenture TMS Therapy® can reduce the symptoms of comorbid anxiety in patients suffering from depression. These new approvals will expand the treatment options of MagVenture TMS Therapy® considerably, which has been CE approved for Major Depressive Disorder (MDD) since 2011.
MagVenture TMS Therapy is an advanced neuromodulation technology that uses magnetic pulses to stimulate the affected areas in the brain. MagVenture TMS Therapy is a well-proven treatment offered as an outpatient, non-invasive procedure with optimized patient comfort.
Most common side effects are headache and nausea.
For more information, please visit www.magventure.com
________________
MagVenture TMS Therapy® - CE approvals
“Treatment of psychoactive substance use disorder (PSUD) in adult patients.”
“As an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).”
“Treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode.”
MagVenture TMS Therapy® - clinical benefit
For subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.
#addiction #ocd #anxiety